Solarea Bio Announces First Close of Series B Financing Round

CAMBRIDGE, Mass. , /PRNewswire/ — Solarea Bio, a clinical stage biotechnology company based in Cambridge, MA developing food-derived microbial-based solutions to aid human health, announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF.

Read More from the Global Wellness News ™

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Save Your Cart
Share Your Cart